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NIPS + FTS = ?

ABSTRACT
Since its introduction less than four years ago, noninvasive prenatal screening (NIPS)
has been widely adopted as a screening tool for women at a high-risk for fetal aneuploidy.
As use expands into the general population, questions arise concerning the integration of
NIPS into preexisting screening routines. We surveyed 208 practicing genetic counselors to
assess the current use of NIPS. Genetic counselors were queried as to the
advantages/disadvantages of offering NIPS to all patients regardless of a priori risk. Results
indicate substantial variation in practice. The majority of participants report offering NIPS in
conjunction with another method of screening for fetal aneuploidy, indicating that NIPS is
being used as an addition rather than as a replacement. Most offer NIPS with another form
of screening, predominantly either first trimester ultrasound, NT, and an MSAFP (45.1%,
n=78), or first trimester serum screening, with or without an NT, and an MSAFP (19.7%,
n=34). Counselors are evenly split on the merits of expanding the use of NIPS to the general
population (con: 55.3%, n=105; pro: 44.7%, n=85). The lack of consensus among
respondents suggests that practice guidelines might benefit counselors at this time. In
addition, the respondents emphasize the significance of better educating providers about the
risks, benefits, and limitations of the test.

KEY WORDS
Noninvasive prenatal screening, Non-invasive prenatal testing, Cell-free DNA, Genetic
counseling, Prenatal screening, Aneuploidy
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INTRODUCTION
The introduction of noninvasive prenatal screening (NIPS) technology has generated
considerable interest, as it promises to be a screen with higher detection rates and lower false
positive rates than preexisting screening methods, minimal physical risk to mother and fetus,
and information on multiple chromosomal conditions. As centers across the country increase
their use of this new technology, it is important to carefully consider the benefits, risks, and
limitations of NIPS relative to alternative screening tests to determine how best to integrate
this tool into the existing machinery of prenatal screening.
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BACKGROUND
Existing guidelines
In December 2012, the American Congress of Obstetricians and Gynecologists
(ACOG) and the Society of Maternal-Fetal Medicine (SMFM) approved the use of NIPS in
high-risk women. This joint committee opinion did not endorse the use of NIPS in women at
a low-risk for fetal aneuploidy due to a lack of adequate performance studies (ACOG, 2012).
The American College of Medical Genetics and Genomics (ACMG) took a similar stance in
a policy statement published in February 2013 (Gregg et al., 2013), emphasizing that NIPS
should not replace a first trimester ultrasound or invasive testing. In addition, the authors
underscored that this technology is a screen and not a diagnostic test. A National Society of
Genetic Counselors (NSGC) position paper, published in January 2013 reminded providers
that this screening should not be considered first-tier testing and highlighted the importance
of pre and post-test counseling (Devers et al., 2013). As of now, these position statements
have not been revised, and currently none of the major organizations support the use of NIPS
in the low-risk population.
Sensitivity and specificity of noninvasive prenatal screening technology in the general
population
Four main companies pioneered the clinical use of NIPS, using cell-free DNA
(cfDNA) to assess a pregnancy’s risk for certain aneuploidies and other chromosomal
abnormalities. These four companies are Sequenom, Verinata (since purchased by Illumina),
Ariosa Diagnostics, and Natera. Recently, more laboratories have announced that they will
offer their own version of NIPS, indicating that the testing may soon become less specialized.
The four primary companies all use different methods and the screens vary in terms of what
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chromosome abnormalities are covered. For some of the tests, patients must choose to opt in
for studies of sex chromosomes and/or microdeletions/microduplications. Each company
uses its own methodology for NIPS, and their benefits and limitations vary, though all
methods have demonstrated sensitivity and specificity for the identification of Down
syndrome superior to that of traditional fetal screening.
There have been several major studies to evaluate the efficacy of NIPS (Bianchi et al.,
2014; Chetty, Garabedian, & Norton, 2013; Dar et al., 2014; Gil, Quezada, Bregnant,
Ferraro, & Nicolaides, 2013; Nicolaides, Syngelaki, Ashoor, Birdir, & Touzet, 2012; Norton
et al., 2012; Norton, Rose, & Benn, 2013; Pergament et al., 2014). Three studies that focused
on the use of NIPS in the general population or low-risk population (Bianchi et al., 2014;
Nicolaides et al., 2012; Pergament et al., 2014) found that NIPS had comparable sensitivities
and specificities in high and low-risk patients.
Nicolaides et al. (2012) and Bianchi et al. (2014) used NIPS technology with a
sequencing approach in a population with both low and high-risk patients. Their goal was to
see if screening would have the same results in this blended population as had been reported
in high-risk populations. Pergament et al. (2014) employed NIPS with a single-nucleotide
polymorphism (SNP) approach, which proved to have several advantages. In this study, the
authors separated the results by low-risk and high-risk, and then considered them as a whole.
All three studies, despite differences in methodology, concluded that NIPS’s performance is
conserved in the low-risk population.
The Nicolaides et al. (2012) cohort study consisted of 2049 women with a singleton
pregnancy presenting for first trimester screening (FTS). These women had both FTS and
NIPS, allowing the authors to evaluate their relative merits. Trisomy risk scores were given
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for 95.1% (1949 of 2049) of affected cases including all eight fetuses with trisomy 21 and
two of the three fetuses with trisomy 18 (Nicolaides et al., 2012, p. 374.e2). In addition,
99.9% (1937 out of 1939) of euploid cases were labeled as having a <1% risk for trisomy 21
and trisomy 18. NIPS identified trisomies 21 and 18 with a false positive rate of 0.1%
(Nicolaides et al., 2012, p. 374.e2). However, one of the cases of trisomy 18 failed to
generate a result. While this does not match the accuracy of diagnostic testing, it did
demonstrate a higher detection rate and lower false positive rate than traditional FTS.
There were some limitations to this study. First, the median maternal weight was 144
pounds, 22 pounds less than the average weight of an American woman. Median maternal
weight would be expected to be higher in many patient populations in the United States
(Body Measurements, 2012), and higher weight is a major risk factor for low fetal fraction
and resulting NIPS failure. Second, for phenotypically normal babies, no cytogenetic testing
was done to confirm NIPS results. While it is unlikely that these babies would have trisomy
21 or trisomy 18, they may have had other cytogenetic findings that would have been
apparent on a karyotype and/or microarray. Furthermore, the study included seven
pregnancies with known abnormal karyotypes that would not be picked up on NIPS. It is
possible this number would have been higher if cytogenetic testing had been done on all
newborns. Third, the 2049 women include 100 women who received no result from NIPS.
These test failures were either due to low fetal fraction (46 cases) or assay failure (54 cases).
The 46 cases of low fetal fraction are significant and will also be considered in the context of
the findings from Pergament et al. (2014), which are discussed below. The n of 2049 does
not include an additional 100 women for whom NIPS could not be run because of laboratory
error (70 cases), inadequate sample volume (29 cases), or incorrect labeling (1 case). In
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total, there were 200 women who did not have NIPS results. The authors conclude that the
detection rate of trisomies is a function of assay precision and fetal fraction, not prevalence,
suggesting that the population being tested would not have an effect on the accuracy of the
testing.
Bianchi et al. (2014) was based on the CARE (Comparison of Aneuploidy Risk
Evaluations) study, a prospective, blinded, multicenter study to analyze the performance of
NIPS in comparison to traditional screening. The study enrolled 2042 women that had either
already had or planned to have FTS or a second trimester maternal serum screen (quad).
Eighteen women, (0.9%) did not get a result because of problems during extraction or
sequencing. Of note, 28.5% of the total had NIPS in the third trimester, which represents a
drastic deviation from how this screening would typically be used in practice.
In the CARE study, NIPS performed equally well in a general population as it has in
the high-risk population, and outperformed standard screening. NIPS had lower false
positive rates for trisomy 21 and trisomy 18 than FTS. For trisomy 21, there were six false
positives (0.3%) with NIPS compared to sixty-nine (3.6%) with traditional screening
(Bianchi et al., 2014, p. 803). For trisomy 18, three patients (0.2%) had a false positive with
NIPS while eleven (0.6%) had a false positive with traditional screening (Bianchi et al., p.
803). Of all patients with false positives, none had a false positive on both screens, and both
screens detected all eight cases of aneuploidy (five trisomy 21, two trisomy 18, and one
trisomy 13. Again, for the false positives, assessment at birth included normal physical
exams, but no cytogenetic testing, and confined placental mosaicism or maternal mosaicism
cannot be ruled out (Bianchi et al., 2014, 806).
Out of the 1,051 women in the study by Pergament et al (2014), 533 (50.7%) were
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considered high-risk and 518 (49.3%) were considered low-risk. Participants were not
provided with their NIPS results. NIPS results included risk assessments for trisomy 21,
trisomy 18, trisomy 13, and monosomy X (Turner syndrome). In addition, all NIPS results
were confirmed with cytogenetic testing, closing another gap from previous studies.
Of the women studied, 966 (91.9%) of the NIPS returned a result. The overall
sensitivity (trisomy 21, trisomy 18, trisomy 13, and monosomy X) was 98.1% and the overall
specificity was 99.8%. Again, results suggest that the sensitivity and specificity do not suffer
in the low-risk population (Pergament et al., 2014, p. 6). A significant difference between
the two populations was that NIPS more frequently failed to produce a result in the low-risk
population. The authors attribute this to an earlier gestational age at the time of the blood
draw in the low-risk population, which increases the chances of low fetal fraction.
When looking at the samples from both populations combined, the authors found that
16% (20/125) of the true aneuploidy samples did not produce a result (Pergament et al.,
2014, p. 2). Fifteen of these samples (75%) had low fetal fraction or low fetal fraction and
insufficient data clarity, and ten had a fetal fraction below 3.4%, which is considered to be
below the 1.5th percentile (Pergament et al., 2014, p. 5). From this, the authors conclude that
samples with less than 3.4% fetal fraction were six times more likely to be abnormal than the
samples with a fetal fraction greater than 3.4%, highlighting the importance of following-up
with patients for whom NIPS failed to provide a result.
Despite increased problems with fetal fraction, NIPS maintains a high sensitivity and
specificity in the low-risk population. However, there are issues concerning the positive
predictive value (PPV) of the test. Many studies do not consider PPV and, notably, PPV is
often missing from the materials produced by the laboratories. In a lecture about the
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marketing of NIPS, Stoll (2014a) detailed her analysis of published PPV values, and focused
on one particular laboratory whose values were accessible. She used their quoted sensitivity,
specificity, and PPV, to determine the incidence of Down syndrome, essentially working
backwards. She found that the incidence had to be 1 in 4 in order for the values to be true.
While the laboratory does not disclose the incidence of Down syndrome from their “internal
data,” Stoll was critical of high PPV rates reported by this laboratory, explaining that based
on the accessible values, her independent calculation of PPV was much lower.
Several others have noted the failure to discuss, and the importance, of PPV
(Begleiter & Finley, 2014; Mennuti, Cherry, Morrissette, & Dugoff, 2013; Mennuti, Cherry,
Morrissette, & Dugoff, 2014; Stoll & Lindh, 2015). Begleiter and Finley (2014) highlight
the difference in PPV and sensitivity and specificity. They calculated the PPV, for each of
the four major commercial versions of NIPS, for a 35-year-old woman with no other risk
factors whose screen is positive for Down syndrome. The PPVs ranged from >28% to >80%.
These two companies with the lowest and highest calculated PPVs, both claim specificities
and sensitivities of at least 99%. In this exercise, they emphasize that false positives are a
very real possibility. In a reply to Begleiter and Finley’s letter to the editor, Mennuti et al.
(2014) state that obstetricians must keep in mind that as NIPS is increasingly used for lowrisk women and as other, rarer, conditions are added to the screen, the PPV will drop.
Utility of first trimester screening (FTS) and maternal serum screening in comparison
to NIPS
Use of NIPS has grown and continues to grow very rapidly, accompanying and in
some cases replacing the use of other prenatal screening modalities. In comparing NIPS to
FTS and maternal serum screening, the primary measure is the relative sensitivity and
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specificity of each method. However, there are ancillary benefits of FTS and maternal serum
screening worth consideration.
The argument has been made that if NIPS becomes the standard screen, there will be
no reason to continue taking nuchal translucency measurements (NT) since NT detects only
aneuploidy and has not been proven to be clinically useful for detecting fetal heart defects or
other anomalies (Shulman, 2014). However, some studies suggest that NT has other utility,
and that the first trimester ultrasound screens for more than aneuploidy.
In a comprehensive review, Nicolaides searched PubMed to gather over a decade’s
worth of studies and articles looking at the utility of nuchal translucency and other first
trimester ultrasound findings as screening for chromosome abnormalities (Nicolaides, 2004).
Nicolaides concluded that increased NT can be associated with a variety of conditions,
including, trisomy 21, Turner syndrome, other chromosome abnormalities, fetal
malformations, and genetic syndromes. The cause of the enlarged NT can be cardiac defects,
venous congestion, diaphragmatic hernias, skeletal dysplasias, problems with the
development of the lymphatic system, and more. These causes may be isolated or
syndromic. For example, the fetus could have an isolated heart defect or could have a heart
defect as a result of having Down syndrome (Nicolaides, Heath, & Cicero, 2002). From the
combined data, Nicolaides found that, “the risk of an adverse outcome, which includes
chromosomal and other abnormalities and fetal and postnatal death, increases with NT
thickness from approximately 5% for NT between the 95th percentile and 3.4 mm to 30% for
NT between 3.5 mm and 4.4 mm to 50% for NT of 4.5 to 5.4 mm and 80% for NT of ≥ 5.5
mm” (Nicolaides, 2004, p. 47). While this increased risk does include aneuploidies for
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which NIPS is highly sensitive, it demonstrates that increased NT can be a significant
indicator of other fetal anomalies.
In addition, Nicolaides pointed to the advantages of an early ultrasound. Many major
fetal abnormalities, can be diagnosed at this time, for example, anencephaly, heart defects,
and abdominal wall defects. Identifying at risk fetuses earlier provides more time for further
testing, decision-making, and the option of earlier termination.
There are two important advantages to FTS that, currently, NIPS cannot replace.
One, the use of NIPS has not yet been validated in higher level multiple gestations. Two, an
NT is almost instantaneous and, depending on the laboratory, the serum results of an FTS can
be returned within days. The turnaround time for NIPS is 7-14 days, depending on the
laboratory. In the prenatal setting, this difference in timing can be of great importance to the
patient.
Another point to consider is the utility of the analyte analysis from maternal serum
screening. Certain analytes levels have been linked with poor obstetrical outcomes,
including intrauterine growth restriction, small for gestational age, spontaneous abortion, and
preterm birth (Dugoff, 2010; Gagnon et al., 2008; Suskin Kaplan, Neto, Dar, Dolan, &
Klugman, 2013). Currently, this information cannot be obtained from NIPS. Despite the
correlation between abnormal serum markers and poor obstetrical outcomes, there have not
been any randomized trials to evaluate the efficacy of interventions (Norton et al., 2014).
Thus, it is unclear if there is a true benefit, other than knowledge, to identifying these women
who are at an increased risk for complications.
In addition to the merits of existing screening techniques, it is important to consider
the limitations of NIPS. A study from Mary Norton, Robert Currier, and Laura Jelliffe-

11

NIPS + FTS = ?
	
  

Pawlowski (2014), aimed to compare the number of chromosome abnormalities that would
be found by traditional prenatal screens and NIPS. They found that out of the screen positive
women who had an abnormal invasive testing result (n = 2,993), 16.8% (n=504) had fetal
abnormalities that would not be expected to be picked up by NIPS (Norton et al., 2014). In
addition, there is also the issue of test failure, necessitating redraws. As demonstrated by the
Pergament et al. (2014) study, failures are particularly troubling as these pregnancies may be
at higher risk.
In addition, it is very possible that some clinicians may not be willing to forego the
information that can be obtained from existing prenatal screening that is not included in
NIPS. Therefore the cost of screening may be based on having combinations of these
screens, rather than one or the other.
Purpose of the study
Over the past few years, centers across the world have started using cell-free DNA for
noninvasive prenatal screening (NIPS). It remains unclear how this technology, will be
integrated into existing prenatal screening routines. To date, professional guidelines have not
supported utilizing NIPS universally, however, many centers across the country have already
started offering NIPS to low-risk women. This paper aims to examine the use of NIPS in
current practice, predominantly in the United States and Canada, in order to inform strategies
for the optimal use of both new and existing screening techniques.
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METHODS
Participants
Genetic counselors seeing at least one prenatal patient per week were eligible to
participate.
Instrumentation
The survey consisted of multiple choice and free-response questions that focused on
the participant’s current use of noninvasive prenatal screening and his or her thoughts
regarding how the screening should be used in the near future. The maximum number of
questions a participant could answer was twenty-three. It was initially piloted on a group of
six genetic counselors who were not otherwise affiliated with the study. The feedback from
the pilot was used to improve the language for questions and response choices and ensure
that the questions asked had the greatest potential to answer the research questions. The
survey was administered through SurveyMonkey. No IP addresses were collected and
participants were not asked any identifying questions. Participants were able to return to
previous questions to change their answers and no questions were mandatory.
Procedures
The Julia Dyckman Andrus Institutional Review Board approved the study on
December 17, 2014. An invitation to participate in the study was distributed through the
Student Research Survey Program to the NSGC distribution list on January 13, 2015
(N=3,200). The e-mail briefly described the objectives of the research project and included
the link for the survey and contact information for the primary investigators. Recipients were
welcome to forward the survey to other counselors. Upon following the link, the participants
were directed to the informed consent. A second e-mail sent out to the distribution list on
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January 20, 2015 as a reminder. The survey was open until January 27, 2015.
Data Analysis
A total of 208 submissions were received (n = 208). Two respondents who reported
seeing less than one patient a week were excluded from the survey (n = 206). Data analysis
was performed using SurveyMonkey, Microsoft Excel, and SPSS. The qualitative questions
were analyzed by common theme. This was first done by the research team and then by a
second coder who was otherwise uninvolved with the study. The inter-rater reliability was
calculated for each theme and ranged from 96.7% to 100%, with a mean of 99% (Freelon,
2013).
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RESULTS
Demographics
Respondents answered questions regarding where they practice and their typical
prenatal patient load. The responses to select demographic questions can be found in Table I.
Current Practice
Participants considered their institution’s current use of NIPS. These questions
focused on to whom NIPS is offered and how it is used in relation to other forms of prenatal
screening. These responses are represented in Figure 1 and Table II.
Universal screening
Respondents reflected on their feelings regarding the implementation of universal
NIPS (i.e. offering NIPS to patients both at high and low-risk for fetal aneuploidy). These
responses are recorded in Table III. For qualitative questions, themes that appeared in five or
more responses are represented in the table.
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Table I: Respondent demographic information
10−14
15−19
5−9
20 or more
1-4

N = 204
n
%
61
29.9
52
25.5
44
21.6
27
13.2
20
9.8

Type of institution

University medical center
Private hospital / medical facility
Public hospital / medical facility
Physician’s private practice
Community hospital
Other

81
44
38
30
8
3

39.7
21.6
18.6
14.7
3.9
1.5

Country of practice

United States
Canada
Australia

194
9
2

94.6
4.4
1.0

Region of the United
States

East North Central
Pacific
Mid-Atlantic
South Atlantic
New England
Mountain
West South Central
West North Central
East South Central

33
32
31
28
20
16
14
12
6

17.2
16.7
16.2
14.6
10.4
8.3
7.3
6.3
3.1

Variable
Average number of
prenatal patients seen in
a week
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Figure 1: Approximately how many of the patients who get NIPS at your center/institution,
are seen by genetics?
None
1%

Less than 25%
4%

25-49%
9%
All
45%

50-75%
9%

More than
75%
32%

Table II: Current practice
To whom does your center / practice currently offer NIPS? Please check all
that apply.
Patients who are high-risk for aneuploidy (35 years or older at time of
delivery, positive screen, ultrasound finding, family history)
Low-risk patients who request NIPS
Low-risk patients who present too late for other screening methods or for
some reason cannot have other screening
All patients who present for prenatal care
Other
It is not offered to any patient
At your center / practice, how is NIPS typically offered? Please choose the
answer that reflects how it is most commonly used.
In conjunction with a first trimester ultrasound and NT (no first trimester
serum screening), and an MSAFP
In conjunction with first trimester screening (NT and serum screening, or
serum only), and an MSAFP
Instead of first and/or second trimester screening
In conjunction with sequential screening or integrated screening
In conjunction with an MSAFP
In conjunction with second trimester serum screening

N = 201
n
%
190 94.5
76
45

37.8
22.4

22
12
1

11.0
5.97
0.5

N = 196
n
%
78
45.1
34

19.7

34
13
12
2

19.7
7.5
6.9
1.2
17
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Which of the following abnormal values would you discuss further with the
patient and/or provider, if the patient’s first or second trimester screening
results are low-risk for aneuploidy and neural tube defects? Please chose all
that apply:
Increased NT
Elevated or decreased AFP
Elevated or decreased uE3
Elevated or decreased PAPP-A
Elevated or decreased hCG
Elevated or decreased inhibin
None

N = 194
n
%
182 93.8
139 71.7
127 65.5
126 65.0
86
44.3
62
32.0
5
2.6

Table III: Counselors’ views on the implementation of universal NIPS
Do you believe that NIPS should be offered universally (i.e. to any
N = 190
pregnant woman, regardless of a priori risk)?
n
%
No
105 55.3
Yes
85
44.7
Comments on the universal use of NIPS, by theme:
Need for more studies / lack of validation in low-risk patients
NIPS is a better than other available screens
The importance of patient education / informed consent
Insurance and cost issues
Lower test performance in low-risk patients
The need for provider education / lack of provider understanding
Concern over NIPS being offered outside of genetics / not enough gc’s
Against practice guidelines / no guidelines for implementation
Lack of patient understanding
Concern over loss of information from other screens
Fairness / patient autonomy
Successful validation studies
Availability of other good screens
If NIPS is approved for universal use, how do you think it should be
implemented?
In conjunction with a first trimester ultrasound and NT (no first trimester
serum screening), and an MSAFP
In conjunction with an MSAFP
In conjunction with first trimester screening (NT and serum screening, or
serum only), and an MSAFP
Other
Instead of first and/or second trimester screening
In conjunction with sequential screening or integrated screening
In conjunction with second trimester serum screening

N = 169
n
%
61
36.1
56
33.1
36
21.3
32
18.9
27
16.0
24
14.2
15
8.9
13
7.7
10
5.9
7
4.1
7
4.1
7
4.1
5
3.0
N = 189
n
%
111 58.7
24
20

12.7
10.6

17
9
6
2

9.0
4.8
3.2
1.1
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Which of the following, if any, would you be concerned about losing in a
transition to NIPS (assuming NIPS was done with MSAFP)? Please choose
all that apply.
NT
PAPP-A
uE3
hCG
None
Inhibin
In pregnancies with no indications / known risk factors (other than general
population risk), do you think there should be a gestational age limit for
NIPS?
No
Yes
Comments on the incorporation of NIPS into prenatal screening routines, by
theme:
The importance of patient education / informed consent
The need for provider education / lack of provider understanding
Concern over loss of information from other screens
Insurance and cost issues / impact on institutional finances
Concern over NIPS being offered outside of genetics / not enough genetic
counselors
Lab transparency / sales representatives as educators
Need for investigation into analytes / no proof pregnancy outcome is
improved
Lack of patient understanding

N = 192
n
%
164 85.4
58
30.2
42
21.9
31
16.2
24
12.5
16
8.3
N = 188
n
%
156
32

83.0
17.0

N = 60
n
%
21
35.0
21
35.0
19
31.7
14
23.3
11
18.3
7
6

11.7
10.0

5

8.3
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DISCUSSION
Current use
Almost all respondents (94%, n=190) report that NIPS is routinely offered to women
at higher risk for aneuploidy (35 years or older at delivery, positive screen, ultrasound
finding, family history). Only one respondent (0.5%) said that NIPS is not offered currently
offered to any patients.
The majority of respondents report using NIPS in conjunction with another form of
screening in the first trimester. It is frequently offered in conjunction with a first trimester
ultrasound, NT, and an MSAFP (45.1%, n=78), or in conjunction with first trimester serum
screening, with or without an NT, and an MSAFP (19.7%, n=34). A small number of
counselors report that it is offered with another form of serum screening alone: 7.5% (n=13)
sequential or integrated screening, and 1.2% (n=2) for second trimester serum screening.
Only 19.7% (n=34) of participants responded that it is typically performed instead of first or
second trimester screening. Responses suggest that in the majority of cases, NIPS is not
replacing other screens, but being used in addition.
Current practice is extremely varied, both in terms of what combination of testing is
offered and to whom it is offered. While there is consensus around offering NIPS to all highrisk women, there are differences in practice when it comes to the general population. A
substantial minority will use NIPS for low-risk patients at the patient’s request (37.8%,
n=76). Others offer NIPS to low-risk patients who present too late for other screening
methods or for some reason cannot have other screening (22.4%, n=45), and 11.0% (n=22)
offer it to all patients who present for prenatal care.
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UNIVERSAL USE
NIPS in the general population
Currently, centers rarely offer NIPS to all obstetrical patients, thus the extensive use
of NIPS in the general population would seem to be a major shift in practice. Respondents
were evenly split on the issue of whether or not NIPS should be offered to all women, with
44.7% (n=85) in favor of universal access. In comments, the predominant theme cited in
support of universal NIPS was that NIPS is better than other available screens (33.1%, n=56).
Counselors touched on the issue of fairness (4.1%, n=7): “Everyone should be offered the
best available screen with the highest detection rate and lowest false positive rate.” Some
respondents also mentioned the existence of successful validation studies (4.1%, n=7): “A
number of studies have shown that the efficacy of NIPS for common aneuploidy (PPV, False
positive rate etc.) is superior to other available screening tests in both high and low risk
populations.” In addition, one response served as a reminder that ‘traditional’ screening
programs have not been around forever: “Screening tests are continually evolving so it is a
logical next step to move on to the best test.”
Among the arguments against universal NIPS, concerns over the lack of validation
were the most widespread (36.1%, n=61). One counselor responded: “We do not have
validation studies in a low risk population. Without that data, I don't think we can have a
meaningful discussion of results with a patient. I can't give them any data on the possibility
false-positive or false-negative because the test hasn't been validated for their use.”
Respondents in favor and against universal NIPS wrote about education, with 21.3%
(n=36) offering comments focused on the importance of patient education and proper
informed consent: “…I would also hope NIPS is explained well to a patient. At our center, a

21

NIPS + FTS = ?
	
  

genetic counselor is almost always involved if NIPS is ordered so those patients get good
information.” The lack of provider understanding and the need for provider education
(14.2%, n=24), along with the lack of patient understanding (5.9%, n=10) were frequently
used arguments against universal NIPS: “Despite multiple education outreach efforts I'm still
getting referrals from outside offices with either confused providers or confused patients (i.e.
‘I was told I could come see you guys first before scheduling my termination or just go ahead
and schedule the termination’). So until that is a little more under control I hesitate to say
everyone should do it.”
These concerns were revisited when participants were prompted to share comments
on the incorporation of NIPS into prenatal screening routines in general. In response, 35.0%
(n=21) wrote about the importance of patient education, 35.0% (n=21) wrote about the
importance of provider education and/or expressed concern over a lack of provider
understanding, and 8.3% (n=5) expressed concern over a lack of patient understanding. For
example, one respondent said, “Every time we have a false positive or false negative they
[referring obstetricians] are floored. No matter how many times we reiterate that it is a
screening test, they don't hear the message.”
Involvement of genetics professionals
Many participants made a case against non-genetics providers offering NIPS. This
was raised by 8.3% (n=14) in response to the question of whether or not NIPS should be
offered universally, and 18.3% (n=11) included it in their final comments. For example,
“Non-genetic providers (OB/GYNs, MFMs) who order the test, in my experience, DO NOT
understand the accuracy of the test/the meaning of an abnormal result. If they understood
and were willing to properly counsel their patient regarding the results I would be fine
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offering it universally. But when the provider says "But the test is 99%" and the actual PPV
is 10%, I have a problem.”
Although counselors may make a case that use of NIPS in the general population,
where PPV is lower, calls for more rather than less participation by genetic professionals,
logistical hurdles suggest that expanded use will have the opposite effect. In this study, just
under half (45.4%, n=89) of all respondents report that all women who get NIPS are seen by
genetics, and 50% (n=98) report that more than 25% are seen by genetics. Assuming no
radical change in the availability of genetic services, it would be hard to sustain these
numbers if the use of NIPS was expanded. As one respondent noted, “Offering NIPS
involves a great deal of upfront counseling to properly inform the patient of the potential
results. Our system is not currently equipped to handle this amount of patient volume. There
are not enough genetic counselors/ trained health care workers to handle the demand.”
Information from other screens
Counselors were very varied in their responses regarding concerns over what would
be lost if NIPS was performed without other screens. The majority report that they would be
concerned about losing the value of an NT in a complete transition to NIPS (85.4%, n=164).
Most counselors report that they currently routinely discuss any abnormal NT or MSAFP
(93.8%, n=186; 71.7%, n=139), suggesting that losing these sources of information would
negatively impact clinical practice. A smaller number of respondents expressed concern
about losing other analyte values. Of these, PAPP-A was highest at 30.2% (n=58). One
respondent underscored something else that would be lost: “I also feel that we are losing
something important by not having a risk number - when I see a first trimester result that is
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abnormal, especially if highly so, I consider and counsel the patient about the possibility of
genetic conditions other than the condition tested (like Down syndrome).”
Cost and insurance
Because evidence here suggests that NIPS would be an additional screen rather than a
replacement screen, it raises more concerns about cost and insurance coverage. A substantial
number of respondents expressed these concerns when commenting on the implementation of
universal NIPS (18.9%, n=32). Specific points of concern included insurance coverage for
multiple screens, the cost to the patients, the financial impact on the department, and the cost
to the overall system. One respondent wrote, “There are very good screens already available
for this population at a much lower cost. If NIPS becomes cheaper than other serum
screening this may be appropriate to offer. Population screening needs to be as cost effective
as possible.” Similar anxieties also emerged in the final comments, where 23.3% (n=14)
expressed concern about cost and/or reimbursement, such as this: “I think it is a great test,
but there needs to be a discussion about expense and who is paying. We don't need to be
doing a $2,000 test on a low risk person when a $160 test will do.” Investigations into the
cost effectiveness of testing as well as practice guidelines will likely have a strong impact on
insurance coverage and thus the cost to the patients.
Study limitations
The survey was distributed through the National Society of Genetic Counselors
(NSGC) distribution list, which includes only members of NSGC. The experiences and
opinions of non-members could not be incorporated into this study. In addition, the “open
rate” for the first email was 27.7% and 24.9% for the reminder email. As with any study,
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those who are interested in and have strong feelings on the subject are the ones most likely to
respond.
Looking forward
Based on this data, there is no consensus among genetic counselors on the best use of
NIPS in high-risk or general populations. There is large variability in both current practice
and opinions on what should be done going forward. However, the responses suggest that at
least when initially implemented, universal NIPS should be offered in conjunction with some
form of first trimester screening and an MSAFP. Counselors expressed misgivings about
how to proceed with NIPS. This indicates that practice guidelines would be useful to provide
consistency, expert review of the costs and benefits, and a standard of care. The careful
consideration of revised prenatal screening routines is crucial to ensure patients receive the
best possible care.

25

NIPS + FTS = ?

REFERENCE LIST
Abu-rustum, R. S., Daou, L., & Abu-rustum, S. E. (2010). Role of First-Trimester
Sonography. Journal of Ultrasound in Medicine, 29, 1445–1452.
Ariosa Diagnostics. (2012). Comments on ACOG Guidelines for Non-Invasive Prenatal
Testing. doi:10.1016/j.ajog.2012.05.021.3
Ashoor, G., Syngelaki, a., Poon, L. C. Y., Rezende, J. C., & Nicolaides, K. H. (2013). Fetal
fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: Relation to
maternal and fetal characteristics. Ultrasound in Obstetrics and Gynecology, 41(October
2012), 26–32. doi:10.1002/uog.12331
Atzei, a, Gajewska, K., Huggon, I. C., Allan, L., & Nicolaides, K. H. (2005). Relationship
between nuchal translucency thickness and prevalence of major cardiac defects in
fetuses with normal karyotype. Ultrasound in Obstetrics & Gynecology, 26(2), 154–7.
doi:10.1002/uog.1936
Bianchi, D. W., Parker, R. L., Wentworth, J., Madankumar, R., Saffer, C., Das, A. F., et al.
(2014). DNA sequencing versus standard prenatal aneuploidy screening. The New
England Journal of Medicine, 370(9), 799–808. doi:10.1056/NEJMoa1311037
Begleiter, M. L., & Finley, B. E. (2014). Positive predictive value of cell free DNA analysis.
American Journal of Obstetrics and Gynecology, 211(July), 81.
Dar, P., Curnow, K. J., Gross, S. J., Hall, M. P., Stosic, M., Demko, Z., et al. (2014). Clinical
experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. American Journal of Obstetrics and Gynecology.
doi:10.1016/j.ajog.2014.08.006

26

NIPS + FTS = ?
	
  

Demers, L. (2014). NIPS: A call to embrace and educate! [Blog post]. Retrieved from
http://thednaexchange.com/2014/02/11/guest-post-nips-a-call-to-embrace-and-educate/
Devers, P. L., Cronister, A., Ormond, K. E., Facio, F., Brasington, C. K., & Flodman, P.
(2013). Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the
National Society of Genetic Counselors. Journal of Genetic Counseling, 22(3), 291–5.
doi:10.1007/s10897-012-9564-0
Dugoff, L. (2010). First- and second-trimester maternal serum markers for aneuploidy and
adverse obstetric outcomes. Obstetrics and Gynecology, 115(5), 1052–1061.
doi:10.1097/AOG.0b013e3181da93da
Freelon, D. (2013). ReCal OIR: Ordinal, interval, and ratio intercoder reliability as a web
service. International Journal of Internet Science, 8(1), 10-16.
Gagnon, A., & Wilson, R. D. (2008). Obstetrical complications associated with abnormal
maternal serum markers analytes. Journal of Obstetrics and Gynaecology Canada,
(217).
Gil, M. M., Quezada, M. S., Bregant, B., Ferraro, M., & Nicolaides, K. H. (2013).
Implementation of maternal blood cell-free DNA testing in early screening for
aneuploidies. Ultrasound in Obstetrics and Gynecology, 42(April), 34–40.
doi:10.1002/uog.12504
Grati, F. R., Malvestiti, F., Ferreira, J. C. P. B., Bajaj, K., Gaetani, E., Agrati, C., et al.
(2014). Fetoplacental mosaicism: potential implications for false-positive and falsenegative noninvasive prenatal screening results. Genetics in Medicine: Official Journal
of the American College of Medical Genetics, (October 2013), 1–5.
doi:10.1038/gim.2014.3

27

NIPS + FTS = ?
	
  

Gregg, A. R., Gross, S. J., Best, R. G., Monaghan, K. G., Bajaj, K., Skotko, B. G., et al.
(2013). ACMG statement on noninvasive prenatal screening for fetal aneuploidy.
Genetics in Medicine  : Official Journal of the American College of Medical Genetics,
15(5), 395–8. doi:10.1038/gim.2013.29
Horsting, J. M. H., Dlouhy, S. R., Hanson, K., Quaid, K., Bai, S., & Hines, K. A. (2014).
Genetic counselors’ experience with cell-free fetal DNA testing as a prenatal screening
option for aneuploidy. Journal of Genetic Counseling, 23(3), 377–400.
doi:10.1007/s10897-013-9673-4
Huang, J., Poon, L. C., Akolekar, R., Choy, K. W., Leung, T. Y., & Nicolaides, K. H. (2014).
Is high fetal nuchal translucency associated with submicroscopic chromosomal
abnormalities on array CGH? Ultrasound in Obstetrics and Gynecology, 43(April),
620–624. doi:10.1002/uog.13384
Hui, L. (2013). Non-invasive prenatal testing for fetal aneuploidy: Charting the course from
clinical validity to clinical utility. Ultrasound in Obstetrics and Gynecology, 41, 2–6.
doi:10.1002/uog.12360
Mennuti, M. T., Cherry, A. M., Morrissette, J. J. D., & Dugoff, L. (2013). Is it time to sound
an alarm about false-positive cell-free DNA testing for fetal aneuploidy? American
Journal of Obstetrics and Gynecology, 209(5), 415–419.
doi:10.1016/j.ajog.2013.03.027
Mennuti, M. T., Dugoff, L., Morrissette, J. J. D., & Cherry, A. M. (2014). Reply. American
Journal of Obstetrics and Gynecology, 211(July), 81. doi:10.1016/j.ajog.2014.01.015
Musci, T. J., Fairbrother, G., Batey, A., Bruursema, J., Struble, C., & Song, K. (2013). Noninvasive prenatal testing with cell-free DNA: US physician attitudes toward

28

NIPS + FTS = ?
	
  

implementation in clinical practice. Prenatal Diagnosis, 33, 424–428.
doi:10.1002/pd.4091
National Society of Genetic Counselors. (2014). 2014 Professional status survey: executive
summary. Retrieved from http://nsgc.org/p/cm/ld/fid=68
Nicolaides, K. H. (2004). Nuchal translucency and other first-trimester sonographic markers
of chromosomal abnormalities. American Journal of Obstetrics and Gynecology,
191(1), 45–67. doi:10.1016/j.ajog.2004.03.090
Nicolaides, K. H. (2011a). A model for a new pyramid of prenatal care based on the 11 to 13
weeks’ assessment. Prenatal Diagnosis, 31, 3–6. doi:10.1002/pd.2685
Nicolaides, K. H. (2011b). Turning the pyramid of prenatal care. Fetal Diagnosis and
Therapy, 29(3), 183–96. doi:10.1159/000324320
Nicolaides, K. H., Syngelaki, a., Gil, M., Atanasova, V., & Markova, D. (2013). Validation
of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal
detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenatal Diagnosis, 33,
575–579. doi:10.1002/pd.4103
Nicolaides, K. H., Syngelaki, A., Ashoor, G., Birdir, C., & Touzet, G. (2012). Noninvasive
prenatal testing for fetal trisomies in a routinely screened first-trimester population.
American Journal of Obstetrics and Gynecology, 207(5), 374.e1–6.
doi:10.1016/j.ajog.2012.08.033
Norton, M. E., Brar, H., Weiss, J., Karimi, A., Laurent, L. C., Caughey, A. B., et al. (2012).
Non-Invasive Chromosomal Evaluation (NICE) Study: Results of a multicenter
prospective cohort study for detection of fetal trisomy 21 and trisomy 18. American

29

NIPS + FTS = ?
	
  

Journal of Obstetrics and Gynecology, 207(2), 137.e1–137.e8.
doi:10.1016/j.ajog.2012.05.021
Norton, M. E., Jelliffe-Pawlowski, L. L., & Currier, R. J. (2014). Chromosome abnormalities
detected by current prenatal screening and noninvasive prenatal testing. Obstetrics &
Gynecology, 124, 979–986. doi:10.1097/AOG.0000000000000452
Pergament, E., Cuckle, H., Zimmermann, B., Banjevic, M., Sigurjonsson, S., Ryan, A., et al.
(2014). Single-nucleotide polymorphism-based noninvasive prenatal screening in a
high-risk and low-risk cohort. Obstetrics and Gynecology, 124(2 Pt 1), 210–8.
doi:10.1097/AOG.0000000000000363
Resta, R. (2014). NIPS SPIN [Blog post]. Retrieved from
http://thednaexchange.com/2014/04/21/nips-spin/
Salomon, L. J., Alfirevic, Z., Bilardo, C. M., Chalouhi, G. E., Ghi, T., Kagan, K. O., et al.
(2013). ISUOG practice guidelines: performance of first-trimester fetal ultrasound scan.
Ultrasound in Obstetrics & Gynecology: The Official Journal of the International
Society of Ultrasound in Obstetrics and Gynecology, 41(1), 102–13.
doi:10.1002/uog.12342
Shulman, L. (2014). The science of pregnancy management: moving beyond NIPT and
through the continuum of care. Presented at the American College of Medical Genetics
and Genomics Annual Clinical Genetics Meeting in Nashville, TN.
Sparks, A. B., Struble, C. a, Wang, E. T., Song, K., & Oliphant, A. (2012). Noninvasive
prenatal detection and selective analysis of cell-free DNA obtained from maternal
blood: evaluation for trisomy 21 and trisomy 18. American Journal of Obstetrics and
Gynecology, 206(4), 319.e1–9. doi:10.1016/j.ajog.2012.01.030

30

NIPS + FTS = ?
	
  

Stoll, K. (2013a). NIPS and the threat to informed decision making [Blog post]. Retrieved
from http://thednaexchange.com/2013/11/04/nips-and-the-threat-to-informed-decisionmaking/
Stoll, K. (2013b). NIPS is not diagnostic – convincing our patients and convincing ourselves
[Blog post]. Retrieved from http://thednaexchange.com/2013/07/11/guest-post-nips-isnot-diagnostic-convincing-our-patients-and-convincing-ourselves/
Stoll, K. (2014a). Non-invasive prenatal screening: data, marketing, and women’s choices.
Presented at the National Society of Genetic Counselors Annual Education Conference.
Stoll, K. (2014b). NIPS: microdeletions, macro questions [Blog post]. Retrieved from
http://thednaexchange.com/2014/11/02/guest-post-nips-microdeletions-macro-questions/
Stoll, K., & Lindh, H. (2015). The DNA Exchange Guest Post  : PPV Puffery  ? Sizing Up
NIPT Statistics [Blog post]. Retrieved from
http://thednaexchange.com/2015/05/04/guest-post-ppv-puffery-sizing-up-nipt-statistics/
Suskin Kaplan, B., Neto, N., Dar, P., Dolan, S. M., & Klugman, S. (2014). The value of the
“double positive” first trimester screen. Poster presented at the American College of
Medical Genetics and Genomics Annual Clinical Genetics Meeting in Nashville, TN
Taylor, J. B., Chock, V. Y., & Hudgins, L. (2014). NIPT in a clinical setting: an analysis of
uptake in the first months of clinical availability. Journal of Genetic Counseling, 23(1),
72–8. doi:10.1007/s10897-013-9609-z
Telesca, S. (2013). Non-invasive prenatal testing: experiences, thoughts, and concerns of
prenatal genetic counselors. Sarah Lawrence College.
The American College of Obstetricians and Gynecologists, & Medicine and The Society for
Maternal-Fetal Medicine. (2012). Committee Opinion. Committee Opinion 545.

31

NIPS + FTS = ?
	
  

Wapner, R. J., Babiarz, J. E., Levy, B., Stosic, M., Zimmermann, B., Sigurjonsson, S., et al.
(2014). Expanding the scope of noninvasive prenatal testing: detection of fetal
microdeletion syndromes. American Journal of Obstetrics and Gynecology, 212(3),
332.e1–332.e9. doi:10.1016/j.ajog.2014.11.041
Wicklund, C., & Trepanier, A. (2014). Adapting genetic counseling training to the genomic
era: more an evolution than a revolution. Journal of Genetic Counseling, 23(4), 452–4.
doi:10.1007/s10897-014-9690-y
Wilson, K. L., Czerwinski, J. L., Hoskovec, J. M., Noblin, S. J., Sullivan, C. M., Harbison,
A., et al. (2013). NSGC practice guideline: prenatal screening and diagnostic testing
options for chromosome aneuploidy. Journal of Genetic Counseling, 22(1), 4–15.
doi:10.1007/s10897-012-9545-3

32

